Cáncer de pulmón

Volver al artículo.

Referencias para el artículo

  1. Eichholzer M. Ernahrung und Krebs. Ther Umsch 2000;57:146–51 [review in German].
  2. Le Marchand L, Murphy SP, Hankin JH, et al. Intake of flavonoids and lung cancer. J Natl Cancer Inst 2000;92:154–60.
  3. Knekt P, Jarvinen R, Seppanen R, et al. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol 1997;146:223–30.
  4. Hertog MGL, Kromhout D, Aravanis C, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the Seven Countries Study. Arch Intern Med 1995;155:381–6.
  5. Levy J, Bosin E, Feldman B, et al. Lycopene is a more potent inhibitor of human cancer cell proliferation than either α-carotene or β-carotene. Nutr Cancer 1995;24:257–66.
  6. Giovannucci E. Tomatoes, tomato-based products, lycopene and cancer: Review of the epidemiologic literature. J Natl Cancer Inst 1999;91:317–331.
  7. Giovannucci E. Tomatoes, tomato-based products, lycopene and cancer: Review of the epidemiologic literature. J Natl Cancer Inst 1999;91:317–31.
  8. Sinha R, Kulldorff M, Curtin J, et al. Fried, well-done red meat and risk of lung cancer in women (United States). Cancer Causes Control 1998;9:621–30.
  9. Deneco-Pellegrini H, De Stefani E, Ronco A, et al. Meat consumption and risk of lung cancer; a case-control study from Uruguay. Lung Cancer 1996;14:195–205.
  10. Mohr DL, Blot WJ, Tousey PM, et al. Southern cooking and lung cancer. Nutr Cancer 1999;35:34–43 [review].
  11. Wynder EL, Herbert JR, Kabat GC. Association of dietary fat and lung cancer. J Natl Cancer Inst 1987;79:631–7.
  12. De Stefani E, Deneo-Pellegrini H, Mendilaharsu M, et al. Dietary fat and lung cancer: a case-control study in Uruguay. Cancer Causes Control 1997;8:913–21.
  13. Wu Y, Zheng W, Sellers TA, et al. Dietary cholesterol, fat, and lung cancer incidence among older women: the Iowa Women’s Health Study (United States). Cancer Causes Control 1994;5:395–400.
  14. Alavanja MCR, Brown CC, Swanson C, Brownson RC. Saturated fat intake and lung cancer risk among nonsmoking women in Missouri. J Natl Cancer Inst 1993;85:1906–16.
  15. Alavanja MCR, Swansons C, Brown C, Brownson R. Re: Lung cancer: another consequence of a high-fat diet? J Natl Cancer Inst 1994;86:314 [letter].
  16. Veierod MB, Laake P, Thelle DS. Dietary fat intake and risk of lung cancer: a prospective study of 51,452 Norwegian men and women. Eur J Cancer Prev 1997;6:540–9.
  17. De Stefani E, Deneo-Pellegrini H, Mendilaharsu M, et al. Dietary fat and lung cancer: a case-control study in Uruguay. Cancer Causes Control 1997;8:913–21.
  18. Hinds MW, Kolonel LN, Hankin JH, Lee J. Dietary cholesterol and lung cancer risk in a multiethnic population in Hawaii. Int J Cancer 1983;32:727–32.
  19. Shekelle RB, Rossof AH, Stamler J. Dietary cholesterol and incidence of lung cancer: the Western Electric Study. Am J Epidemiol 1991;134:480–4.
  20. Wu Y, Zheng W, Sellers TA, et al. Dietary cholesterol, fat, and lung cancer incidence among older women: the Iowa Women’s Health Study (United States). Cancer Causes Control 1994;5:395–400.
  21. Pierce RJ, Kune GA, Kune S, et al. Dietary and alcohol intake, smoking pattern occupational risk, and family history in lung cancer patients: results of a case-control study in males. Nutr Cancer 1989;12:237–48.
  22. Rose DP, Connolley JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999;83:217–44.
  23. De Stefani E, Deneo-Pellegrini H, Mendilaharsu M, et al. Dietary sugar and lung cancer: a case-control study in Uruguay. Nutr Cancer 1998;31:132–7.
  24. Murphy GP, Lawrence W, Lenhard RE (eds). American Cancer Society Textbook of Clinical Oncology, second edition. Atlanta: American Cancer Society, Inc., 1995, 221 [review].
  25. Zhong L, Goldberg MS, Parent ME, Hanley JA. Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis. Lung Cancer 2000;27:3–18.
  26. Murphy GP, Lawrence W, Lenhard RE (eds). American Cancer Society Textbook of Clinical Oncology, second edition. Atlanta: American Cancer Society, Inc., 1995, 221 [review].
  27. Lubin JR, Boice JD Jr. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. J Natl Cancer Inst 1997;89:49–57.
  28. Heimburger DC, Alexander B, Birch R, et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. JAMA 1988;259:1525–30.
  29. Heimburger DC, Alexander B, Birch R, et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. JAMA 1988;259:1525–30.
  30. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996;88:1550–9.
  31. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029–35.
  32. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145–9.
  33. Doering W von E. Antioxidant vitamins, cancer and cardiovascular disease. N Engl J Med 1996;335:1065 [letter].
  34. Ben-Amotz A, Levy Y. Bioavailability of a natural isomer mixture compared with synthetic all-transβ-carotene in human serum. Am J Clin Nutr 1996;63:729–34.
  35. Yeum K-J, Zhu S, Xiao S, et al. β-carotene intervention trial in premalignant gastric lesions. J Am Coll Nutr 1995;14:536 [Abstract 48].
  36. Johnson EJ, Krinsky NI, Russell RM. Serum response of all-trans and 9-cis isomers of β-carotene in humans. J Am Coll Nutr1996;15:620–4.
  37. Shekelle RB, Liu S, Raynor WJ Jr, et al. Dietary vitamin A and risk of cancer in the Western Electric Study. Lancet1981;2:1185–90.
  38. Medina D. Mechanisms of selenium inhibition of tumorigenesis. Adv Exp Med Biol 1986;206:465–72.
  39. Beisel WR. Single nutrients and immunity. Am J Clin Nutr 1982;35:417–68.
  40. Medina D, Morrison DG. Current ideas on selenium as a chemopreventative agent. Pathol Immunopathol Res 1988;7:187–99.
  41. Shamberger RJ, Rukoven E, Lonfield AK, et al. Antioxidants and cancer. I. Selenium in the blood of normals and cancer patients. J Natl Cancer Inst 1973;4:863–70.
  42. Burney PGJ, Comstock GW, Morris JS. Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. Am J Clin Nutr 1989;49:895–900.
  43. Toma S, Micheletti A, Giacchero A, et al. Selenium therapy in patients with precancerous and malignant oral cavity lesions: preliminary results. Cancer Detection Prev 1991;15:491–3.
  44. Willett WC, Polk BF, Morris JS, et al. Prediagnostic serum Selenium and risk of cancer. Lancet 1983;42:130–4.
  45. Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, ß-carotene, retinol, and subsequent bladder cancer. Cancer Res 1989;49:6144–8.
  46. Jaskiewicz K, Marasas WF, Rossouw JE, et al. Selenium and other mineral elements in populations at risk for esophageal cancer. Cancer 1988;62:2635–9.
  47. Knekt P, Aromaa A, Maatela J, et al. Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst 1990;82:864–8.
  48. Yu M-W, Horng I-S, Hsu K-H, et al. Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection. Am J Epidemiol 1999;150:367–74.
  49. Scieszka M, Danch A, Machalski M, Drozdz M. Plasma selenium concentration in patients with stomach and colon cancer in the Upper Silesia. Neoplasma 1997;44:395–7.
  50. Knekt P, Marniemi J, Teppo L, et al. Is low selenium status a risk factor for lung cancer? Am J Epidemiol 148:975–82.
  51. Fex G, Pettersson B, Akesson B. Low plasma selenium as a risk factor for cancer death in middle-aged men. Nutr Cancer 1987;10:221–9.
  52. Salonen J, Salonen R, Lappetelainen R, et al. Risk of cancer in relation to serum concentrations of selenium and vitamins A and E; matched case-control analysis of prospective data. BMJ 1985;290:417–20.
  53. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996;276:1957–63.
  54. Menkes MS, Comstock GW, Vuilleumier JP, et al. Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer. N Engl J Med 1986;315:1250–4.
  55. Eichholzer M, Stahelin HB, Gey F, et al. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel Study. Int J Cancer 1996;66:145–50.
  56. Knekt P. Vitamin E and smoking and the risk of lung cancer. Ann NY Acad Sci 1993;686:280–7; discussion 287–8.
  57. Mayne ST, Janerich DT, Greenwald P, et al. Dietary beta carotene and lung cancer risk in U.S. nonsmokers. J Natl Cancer Inst 1994;86:33–8.
  58. [No authors listed]. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029–35.
  59. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993;11:1216–22.
  60. van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst 2000;92:977–86.
  61. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150–5.
  62. Lissoni P, Barni S, Crispino S, et al. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 1989;25:789–95.
  63. Neri B, De Leonardis V, Gemelli MT, et al. Melatonin as biological response modifier in cancer patients. Anticancer Res 1998;18:1329–32.
  64. Lissoni P, Barni S, Crispino S, et al. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 1989;25:789–95.
  65. Lissoni P, Barni S, Ardizzoia A, et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 1994;73:699–701.
  66. Lissoni P, Barni S, Ardizzoia A, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 1992;49:336–9.
  67. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996;32A:1340–3.
  68. Lissoni P, Barni S, Tancini G, et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994;69:196–9.
  69. Lissoni P, Brivio F, Ardizzoia A, et al. Subcutaneous therapy with low-dose interlekin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori 1993;79:401–4.
  70. Aldeghi R, Lissoni P, Barni S, et al. Low-dose interlekin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer 1994;30A:167–70.
  71. Lissoni P, Paolorossi F, Tancini G, et al. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. Br J Cancer 1996;74:1466–8.
  72. Lissoni P, Barni S, Mandalà, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999;35:1688–92.
  73. Lissoni P, Brivio O, Brivio F, et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J Pineal Res 1996;21:239–42.
  74. Neri B, Fiorelli C, Moroni F, et al. Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. Cancer 1994;73:315–9.
  75. Lissoni P, Barni S, Ardizzoia A, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 1992;49:336–9.
  76. Lissoni P, Barni S, Ardizzoia A, et al. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology 1992;49:336–9.
  77. William Judy, personal communication.
  78. Allen JI, Bell E, Boosalis MG, et al. Association between urinary zinc excretion and lymphocyte dysfunction in patients with lung cancer. Am J Med 1985:79:209–15.
  79. Jatoi A, Daly BD, Kramer G, Mason JB. A cross-sectional study of vitamin intake in postoperative non-small cell lung cancer patients. J Surg Oncol 1998;68:231–6.
  80. Jatoi A, Daly BD, Kramer G, Mason JB. A cross-sectional study of vitamin intake in postoperative non-small cell lung cancer patients. J Surg Oncol 1998;68:231–6.
  81. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000;5:4–27 [review].
  82. Kaibara N, Soejima K, Nakamura T, et al. Postoperative long-term chemotherapy for advanced gastric cancer. Jpn J Surg 1976;6:54–9.
  83. Niimoto M, Hattori T, Tamada R, et al. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 1988;18:681–6.
  84. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994;343:1122–6.
  85. Ogoshi K, Satou H, Isono K, et al. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. Cancer Invest 1995;13:363–9.
  86. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 1993;13:1815–20.
  87. Yun TK. Experimental and epidemiological evidence of the cancer-preventive effects of Panax ginseng C.A. Meyer. Nutr Rev 1996;54(suppl):S71–81.
  88. Cha RJ, Zeng DW, Chang QS. Non-surgical treatment of small cell lung cancer with chemo-radio-immunotherapy and traditional Chinese medicine. Chung Hua Nei Ko Tsa Chih (Chin J Intern Med) 1994;33:462–6.
  89. Kono S, Ikeda M, Tokudome S, Kuratsune M. A case-control study of gastric cancer and diet in northern Kyushu, Japan. Jpn J Cancer Res 1988;79:1067–74.
  90. Gao YT, McLaughlin JK, Blot WJ, et al. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst 1994;86:855–8.
  91. Ji BT, Chow WH, Hsing AW, et al. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 1997;70:255–8.
  92. Fujiki H. Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 1999;125:589–97 [review].
  93. Ohno Y, Wakai K, Genka K, et al. Tea consumption and lung cancer risk: A case-control study in Okinawa, Japan. Jpn J Cancer Res 1995;86:1027–34.
  94. Goldbohm RA, Hertog MGL, Brants HAM, et al. Consumption of black tea and cancer risk: A prospective cohort study. J Natl Cancer Inst 1996;88:93–100.
  95. Heilbrun L, Nomura A, Stemmermann G. Black tea consumption and cancer risk: A prospective study. Br J Cancer 1986;54:677–83.
  96. Phillips RL, Snowdon DA. Dietary relationship with fatal colorectal cancer among Seven-Day Adventists. J Natl Cancer Inst 1985;74:307–17.
  97. Sun AS, Ostadal O, Ryznar V, et al. Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement. Nutr Cancer 1999;34:62–9.
  98. Sun AS, Ostadal O, Ryznar V, et al. Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement. Nutr Cancer 1999;34:62–9.
  99. Brinker F. The Hoxsey treatment: Cancer quackery or effective physiological adjuvant? J Naturopathic Med 1996;6:9–24 [review].
  100. Brinker F. The Hoxsey treatment: Cancer quackery or effective physiological adjuvant? J Naturopathic Med 1996;6:9–24 [review].
  101. Austin S, Baumgartner Dale E, DeKadt S. Long term follow-up of cancer patients using Contreras, Hoxsey and Gerson therapies. J Naturopathic Med 1994;5:74–6.
  102. Austin S, Baumgartner Dale E, DeKadt S. Long term follow-up of cancer patients using Contreras, Hoxsey and Gerson therapies. J Naturopathic Med 1994;5:74–6.
  103. Morita K, Kada T, Namiki M. A desmutagenic factor isolated from burdock (Arctium lappa Linne). Mutat Res 1984;129:25–31.
  104. Belkin M, Hardy WG, Perrault A, Sato H. Swelling and vacuolization induced in ascites tumor cells by polysaccharides from higher plants. Cancer Res 1959;19:1050–62.
  105. Morita K, Kada T, Namiki M. A desmutagenic factor isolated from burdock (Arctium lappa Linne). Mutat Res 1984;129:25–31.
  106. Belkin M, Hardy WG, Perrault A, Sato H. Swelling and vacuolization induced in ascites tumor cells by polysaccharides from higher plants. Cancer Res 1959;19:1050–62.
  107. Uckun FM, Chelstrom LM, Finnegan D, et al. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992;79:3116–29.
  108. Uckun FM, Manivel C, Arthur D, et al. In vivo efficacy of B43 (anti-CD19)- pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1992;79:2201–14.
  109. Uckun FM, Chelstrom LM, Irvin JD, et al. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL–1 murine B–cell leukemia. Blood 1992;79:2649–61.
  110. Gunther R, Chelstrom LM, Tuel-Ahlgren L, et al. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Blood 1995;85:2537–45.
  111. Niwa K, Hashimoto M, Morishita S, et al. Preventive effects of Glycyrrhizae radix extract on estrogen-related endometrial carcinogenesis in mice. Jpn J Cancer Res 1999;90:726–32.
  112. Taylor A, McKenna GF, Burlage HM. Anticancer activity of plant extracts. Texas Rep Biol Med 1956;14:538–56.
  113. McKenna GF, Taylor A. Screening plant extracts for anticancer activity. Texas Rep Biol Med 1962;20:214–20.
  114. Belkin M, Hardy WG, Perrault A, Sato H. Swelling and vacuolization induced in ascites tumor cells by polysaccharides from higher plants. Cancer Res 1959;19:1050–62.
  115. Kupchan SM, Karim A. Tumor inhibitors. 114. Aloe emodin: Antileukemic principle isolated from Rhamnus frangula L. Lloydia 1976;39:223–4.
  116. Taylor A, McKenna GF, Burlage HM. Anticancer activity of plant extracts. Texas Rep Biol Med 1956;14:538–56.
  117. Cordell GA, Farnsworth NR. Experimental antitumor agents from plants, 1974–76. Lloydia 1977;40:1–44.
  118. Stermitz FR, Larson KA, Kim DK. Some structural relationships among cytotoxic and antitumor benzophenanthridine alkaloid derivatives. J Med Chem 1973;16:939–40.
  119. American Cancer Society. Hoxsey Method/Bio-Medical Center. CA Cancer J Clin 1990;40:51–5.
  120. Brinker F. The Hoxsey treatment: Cancer quackery or effective physiological adjuvant? J Naturopathic Med 1996;6:9–24 [review].
  121. Personal correspondence, Mildred Nelson, R.N., 1983.